EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will test the influence of rs9557195 genoty (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes, mRNA expression of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migraton assay.
EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). EBI2 is a G protein coupled receptors expressed on the immune cells. EBI2 directs migration and activity of immune cells. Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will recruit patients with Crohn's disease and ulcerative colitis, assess epidemiological and clinical parameters (including clinical activity of IBD) draw blood, isolate lymphocytes, DNA and RNA. The investigators will test the influence of rs9557195 genotype (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes (by FACS using an EBI2-antibody), mRNA expression (by qPCR) of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migration assay.
Study Type
OBSERVATIONAL
Enrollment
340
University Hospital Zurich
Zurich, Switzerland
RECRUITINGEBI2 expression - dependent on rs9557195 allele status (FACS)
EBI2 levels in PBMCs will be determined by FACS, and compared according to allele status of rs9557195
Time frame: at time of inclusion into the study
EBI2 expression - dependent on rs9557195 allele status (RT-PCR)
EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195
Time frame: at time of inclusion into the study
UBAC2 expression - dependent on rs9557195 allele status (RT-PCR)
UBAC2 levels in PBMCs will be determined by RT-PCR, and compared according to 2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195
Time frame: at time of inclusion into the study
Motility of PBMCs dependent on rs9557195 allele status (Boyden chamber)
motility of PBMCs will be assessed using the Boyden chamber and compared according to allele status of rs9557195
Time frame: at time of inclusion into the study
EBI2-expression (FACS) in individuals treated with infliximab vs. vedolizumab
We will compare EBI2 expression as determined by FACS in individuals with infliximab and vedolizumab treatment
Time frame: at time of inclusion into the study
EBI2-expression (FACS) according to gut inflammation
We will compare EBI2 expression (determined by FACS) in IBD patients with severe disease, in remission and in healthy volunteers
Time frame: at time of inclusion into the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.